Low coffers, failed endometrial cancer trial: Karyopharm down 72%

Source Summary

Quickly running out of cash, Karyopharm Therapeutics Inc. found itself in a precarious situation July 30 when top-line phase III results showed Xpovio (selinexor) failed to meet the progression-free survival primary endpoint in endometrial cancer. The Newton, Mass.-based company last reported cash of $91.2 million as of the end of the first quarter (Q1), enough to fund operations through the latter part of Q3. Karyopharm, founded in 2008, is now exploring financings and strategic alternatives.